Hypertension
Conditions
Brief summary
A multicenter, prospective, non-interventional, observational study to evaluate effectiveness and safety of sequential triple combination therapy (amlodipine/losartan/chlorthalidone) in Korean patients with hypertension
Interventions
DRUGAMOPREL TAB 1.67/16.67/4.17mg
Follow-up of subjects prescribed medication in a non-intervention study
Sponsors
Hanmi Pharmaceutical Company Limited
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Korean patients aged 19 years or older diagnosed with hypertension 2. Individuals newly diagnosed with hypertension or currently taking a single antihypertensive drug 3. Individuals for whom administration of Amoprel tablets has been determined based on the researcher's medical judgment 4. Individuals who have heard an explanation of this study and have voluntarily given written consent to participate in the study
Exclusion criteria
1. Individuals falling under the contraindications listed in the precautions for use of Amoprel Tab. or Amozartan Plus Tab. 2. Pregnant women, women who may be pregnant, and nursing mothers 3. Individuals currently participating in an interventional study 4. Individuals deemed unsuitable for participation in this study by the researcher for other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in Systolic Blood Pressure (SBP) relative to baseline | the 6-month time |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| effectiveness of sequential triple combination therapy (amlodipine/losartan/chlorthalidone) | 2, 4, 6 months | Change from baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at 2 and 4 months, and change from baseline in DBP at 6 months |
| Prescription patterns of a triple-therapy-based stepwise treatment strategy | 2, 4, 6 months | Proportion of Participants by Study Drug Dosage at Months 2, 4, and 6 |
| safety of sequential triple combination therapy (amlodipine/losartan/chlorthalidone) | 2, 4 , 6 months | Incidence of Adverse Events During the 6-Month Follow-up Period |
Countries
South Korea
Outcome results
None listed